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Summary: We describe a study by which the establishment of assigned values of a control serum was simulated. The
study covered two controls: The internal known control and a blind control. Seven constituents were analyzed in
10 or 11 laboratories, respectively, yielding a total of 72 sets of analytical values. Each set covered double determi-
nations within approximately 18 series for each sample.
The course of a blind control correlates better with the unknown sample for which assigned values are to be deter-
mined than does a known control. Out of 72 sets 5 sets were found incorrect. Out of these, 2 sets could be recog-
nized exclusively by means of the blind control, and 2 others primarily by means of the known control; one of these
could be detected by means of the double determinations. Consequently, a blind control has a greater control efficiency
than double determinations.
Die Bedeutung einer Blindkontrolle bei der Ermittlung von Sollwerten in Kontrollseren
Ermittlung von Sollwerten in Kontrollieren, L
Zusammenfassung: Wir beschreiben eine Studie, mit deren Hilfe die Ermittlung von Sollwerten eines Kontrollserums
simuliert wurde. Die Studie umfaßte zwei Kontrollen: die interne bekannte Kontrolle und eine Blindkontrolle.
Sieben Bestandteile wurden jeweils in 10 bis 11 Laboratorien analysiert, so daß sich insgesamt 72 Ergebnismengen
ergaben. Jede Ergebnismenge umfaßte für jedes Serum Doppelbestimmungen in ungefähr 18 Serien.
Der Verlauf einer Blindkontrolle korreliert besser mit der unbekannten Probe, für die Sollwerte bestimmt werden
sollen, ajs der Verlauf einer bekannten Kontrolle. Von den 72 Ergebnismengen wurden 5 als fehlerhaft erkannt. Von
diesen korinten 2 allein mit Hilfe der Bjindkontrolle und 2 weitere in erster Linie mit Hilfe der bekannten Kontrolle
erkannt werden. Hiervon konnte eine mit Hilfe der Doppelbestimmungen entdeckt werden. Eine Blindkontrolle
besitzt also größere Kontrolleffizienz als poppelbestimrhungen.
Introduction within each laboratory. Roughly speaking, either few
There are various designs for the establishment of as- laboratories but many determinations are demanded
signed values in control sera (2,3,4). They vary con- or aversely more or fewer laboratories w,th few deter-
•T 1.1 -* *.* ^ u u~ «+ ~ minations are required. Sometimes the arrangement ofsiderably with respect to the number of laboratories, - J·. . . 6
' ' " ' - j x i _ ' r * ;~„+;^«c. the analyses within the laboratories is even prescribedand the number and the arrangement of determinations · * . r0
 as a double determination. Furthermore, the statistical
. methods for the calculation of the assigned value and
*) A preliminary report is given in I.e. (1) its uncertainty interval differ essentially.
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Unfortunately, arguments based on experimental data
for these designs and evaluations have not been reported.
No systematic comparisons between these different
methods and their implications on the assigned value
and its uncertainty interval have been published until
now.
Therefore it was our intention to investigate the in-
fluence of different designs and statistical methods
on the assigned value and uncertainty interval, in order
to elaborate a model which gives accurate assigned
values with acceptable expenditure with a high degree
of security.
It has become standard in the determination of most
blood constituents to monitor the results by appro-
priate control materials. On the other hand it is known
that the results of these controls do not always repre-
sent the correct degree of precision and accuracy in
the clinical laboratory, because controls are handled
with special care. Moreover, previous results from the
same control and the same experiment influence the
technician in reading subsequent values (5,6). Further-
more, the uncertainty interval of the different controls
used by different laboratories may have been established
under different conditions and for different purposes
yielding systematically smaller or broader intervals.
Consequently, the participating reference laboratories
use different procedures to monitor their results.
Finally, different serum-specific problems can arise
from different control sera so that e.g. the values of
the control serum are all correct, whereas the values
of the unknown sample are all systematically wrong.
This would mean that the control is completely in-
effective.
A common control serum was distributed to all partici-
pants in order to check the performance of the labor-
atories uniformly. The common control served as a
blind control, i.e. its assigned values and uncertainty
intervals were known to the project leader only. This
paper describes the errors which were detected by
different control procedures.
In the further papers of this series various statistical
methods are examined with respect to their adequacy.
Different designs for the establishment of assigned
values are compared critically. This will finally lead to
an optimized design and evaluation procedure.
Materials and Methods
The 12 laboratories participating in this study are members of
the Verband der Diagnostica- und Diagnosticageräte-Hersteller
(VDGH, Association of Diagnostics and Diagnostics Instrumen-
tation Manufacturers).
®Monitrol II (Dade), lot no. 58 B, served as the unknown sample
for the establishment of assigned values and their uncertainty
intervals.
The common in-house controls were used as known controls,
namely ®Normosic and PKR (Asid Bonz und Sohn GmbH),
®Kontrollogen L (Behringwerke AG), ©Serodos (Boehringer
Ingelheim Diagnostika GmbH), ®Precindrrh U and E and
®Precipath E and S (Boehringer Mannheim GmbH), and Validate
A (Goedecke AG).
Precinorm U (Boehringer Mannheim GmbH), lot. no. 618, was
used as a blind control.
The study was based on the following constituents and methods:
Greatinine, Jaffe reaction without deproteinization (7, 8, 9),
reading at Hg 492 nm,
glucose, enzymatic with hexokinase/glucose 6-phqsphate
dehydrogenase (10,11, 12), reading at Hg 365 nm,
urea, urease and subsequent Berthelpt reaction (13,14), reading
at Hg 546 nm,
alanine aminotransferase2), standard method of Deutsche
Gesellschaft für Klinische Chemie (15),
aspartate aminotransferased, standard method of Deutsche Ge-
sellschaft fur Klinische Chemie (15),
creatine kinase2), N-acetyl cysteine activated (16, 17),
•y-glutamyltransferase2), substrate -glutamyl 3-carboxy 4-nitro-
anilide (18).
All enzyme activities were measured at 25 °C and Hg 365 nm
except for 7^glutamyltransferase which was read at Hg 405 nm.
The following factors were kept constant in order to avoid
systematic bias due to modifications in the performance of the
analyses: the same type of photometer (EPPENDORF Gerätebau)
was used; the reagents for each constituent were delivered from
one manufacturer and derived from one common lot for all
participants; the analyses were performed at final volumes
greater than 2.0 ml according to the package inserts.
Table 1 shows the number of participating laboratories for
each constituent.
Tab. 1. Number of laboratories participating in the study and
remaining after eliminations.
Constituent
Creatinine
Glucose
Urea
Alanine amino-
transferase
Aspartate amino-
transferase
Creatine kinase
7-Glutamyltransferase
Total
Number of
laboratories
participating3)
10
10
10
11
11
10
10
72
Number of
laboratories
remaining
9
9
9
11
11
9
9
67
a) No constituent was determined by all 12 laboratories parti-
cipating in this study.
Double determinations were performed within approximately
18 independent series, for each of the three sera and in each
laboratory. Table 2 shows mean, standard deviation, median, and
the smallest and the largest analytical value of the series, separ-
ated according to the first and to the second determination of
the double determinations of the unknown sample, and the
standard deviation within series.
We simulated single determinations by using the first values
only of the double determinations.
2) Enzymes: Glutamate-pyruvate-transaminase alanine amino-
transferase = Z-alanine: 2-oxoglutarate aminotransferase
EC 2.6.1.u2;glutamate-oxalacetate-transammase - aspartate
aminotransferase = £-aspartate: 2-oxoglutarate aminotrans-
ferase EC 2.6.1. l;7-glutamyl transferase = (5-glutamyl)-
• peptide: aminoacid 5-glutamyltransferase EC 2.3.2.2;
creatine kinase = ATP: creatine N-phosphotransferase
EC 2.7.3.2.
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Tab. 2. Survey of the original data*) of the unkown sample.
First values
Consti-
tuent
Creatinine
(ìçéïÉ/1)
Glucose
(mmol/1)
Urea
(mmol/1)
Alanine
amino-
transferase
(U/l)
Aspartate
amino-
transferase
(U/i)
Creatine
kinase
Labor-
atoryb)
A
C
D
E
F
G
H
I
J
K
A
C
D
E
F
G
H
I
J
K
A
C
D
E
F
G
H
I
J
K
A
B
C
D
E
F
G
H
I
J
k
A
B
C
E
F
G
Hij
K
L
A
C
D
E
F
G
H
I
j
·*
K
Mean
301
318
306
373
325
319
311
311
302
290
12.0
11.6
12.5
11.8
12.0
12.5
12.3
12.1
11.9
12.5
12.6
13.4
12.8
12.7
13.3
13.4
12.2
13.4
13.0
13.0
64.0
66.3
62.6
62.8
62.0
62.7
65.8
62.2
63.2
59.7
62.5
41.1
40.2
40.3
40.4
39.3
40.6
39.6
39.1
39.8
39.8
40.2
225
158
189* "^
221
221
260
232
204
249
226
SDc)
16
12
8
12
11
8
9
2'
9
9
0.4
0.2
0.2
0.2
0.5
0.2
0.8
0.2
0.3
0.4
0.3
0.3
0.4
0.5
0.3
0.3
1.2
0.2
0.3
0.2
2.1
2.0
1.9
1.5
1.7
1.5
1.1
1.5
0.7
1.3
1.7
1.9
0.9
1.7
1.0
1.9
0.7
1.4
0.6
1.2
1.9i, 2
18
29
28
10
17-
6
16
3
11
14
Mediand)
307
319
307
375
325
321
308
311
303
290
11.9
11.6
12.5
11.8
12.1
12.5
12.2
12.1
11.9
12.5
12.6
13.5
12.8
12.8
13.4
13.4
12.4
13.4
13.1
13.0
64.7
66.9
62.9
62.6
61.8
63.1
66.2
63.1
63.3
59.5
63.2
41.0
40.2
40.6
40.4
39.5
40.6
40.1
39.2
40.0
39.2
40.5
224
160
191
223
223
262
230
204
248
229
Min.e)
265
301
288
348
306
305
298
308
280
270
11.5
11.2
12.0
11.4
11.1
12.0
11.6
11.9
11.4
11.7
12.1
12.9
12.0
11.4
12.8
13.0
10.1
12.9
12 A
12.6
60.2
63.1
58.5
60.5
59.9
59.3
64.2
59.3
62.3
57.4
59.5
38.5
38.7
37.1
39.2
32.5
39.6
38.2
38.2
37.7
38.2
36.7
196
106
119
201
191
250
201
198
227
193
Max.*)
321
342
321
392
346
331
326
315
315
308
12.7
11.9
12.9
12.1
12.6
12.9
14.9
12.5
12.5
12.9
13.1
13.8
13.3
13.6
13.7
13.8
14.8
13.8
13.4
13.3
67.0
70.7
66.3
65.0
66.9
65.0
67.3
65.0
64.4
61.7
64.9
45.4
41.6
43.1
42.5
40.8
41.8
42.1
40.2
42.1
45.4
42.1
257
199
228
235
243
268
253
210
272
243
Second
Mean
301
322
305
382
322
318
308
312
300
286
12.1
11.7
12.5
11.8
12.1
12.5
12.2
12.1
11.9
12.6
12.7
13.3
12.8
12.7
13.3
13.4
12.3
13.3
12.9
12.9
63.4
65.5
63.4
62.2
62.3
62.4
65.6
62.5
63.5
59.5
62.6
40.2
40.2
40.2
40.0
39.3
40.7
39.4
39.3
39.7
40.1
40.4
223
158
191
220
222
260
225
205
249
225
values
SDC)
17
14
10
11
12
8
8
3
9
9
0.5
0.3
0.2
0.2
0.4
0.2
0.5
0.2
0.3
0.2
0.4
0.3
0.3
0.5
0.8
0.3
1.7
0.3
0.2
0.3
1.7
1.5
2.2
1.8
1.1
1.2
1.3
3.1
0.7
1.1
2.2
2.2
1.0
1.5
0.9
1.9
0.7
1.3
0.6
1.5
2.2
1.1
15
28
30
9
16
5
14
4
10
13
Mediand)
303
321
307
385
322
320
306
312
300
286
11.9
11.8
12.5
11.8
12.2
12.5
12.1
12.1
11.9
12.7
12.8
13.4
12.8
12.8
13.4
13.4
12.5
13.3
12.9
12.9
63.0
65.0
63.0
61.8
62.5
62.5
65.8
63.1
63.4
59.7
62.2
39.3
40.2
40.7
40.0
39.9
40.9
40.1
39.5
39.7
39.4
40.5
226
159
197
220
221
260
223
206
248
230
Min.e)
265
298
286
354
303
304
297
307
276
271
11.6
11.2
12.2
11.5
11.3
12.2
11.5
11.9
11.4
12.2
12.1
12.8
12.0
11.5
11.2
13.0
9.5
12.9
12.5
12.5
61.0
63.1
60.7
57.8
59.9
60.6
63.1
55.4
62.3
57.7
59.1
37.7
38.7
37.7
38.7
32.5
39.3
38.2
38.2
37.8
36.2
38.2
200
108
134
203
201
251
201
197
229
197
Max.*)
331
346
321
397
341
330
324
316
311
303
13.2
12.1
13.1
12.1
12.7
13.0
13.5
12.3
12.7
12.9
13.5
13.8
13.2
13.5
14.2
14.0
15.6
13.9
13.2
13.3
67.4
68.8
67.6
64.5
64.4
65.0
67.5
68.8
64.8
61.2
66.2
44.5
42.5
42.6
41.1
41.4
41.8
42.1
39.8
43.5
46.3
42.8
249
196
235
235
240
268
253
211
265
241
SD
within
series
3
7
5
7
3
3
2
2
5
5
0.2
0.2
0.1
0.1
0.3
0.2
0.4
0.2
0.1
0.2
0.3
0.2
0.1
0.3
0.6
0.2
1.2
0.2
0.2
0.1
1.4
1.5
1.1
1.6
1.2
0.8
0.4
1.8
0.7
1.0
1.0
1.6
0.3
0.9
0.5
0.5
0.4
0.9
0.6
0.5
1.0
0.5
8
5
27
3
7
3
9
3
5
4
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Tab. 2. Continued.
First values
Consti-
tuent
7-Glu-
tamyl-
transferase
(U/l)
Labor-
atory b)
A
C
D
E
F
G
H
I
J
K
Mean
43.7
48.3
47.8
48.3
47.4
48.9
46.7
47.7
47.5
46.1
SDc)
1.7
1.7
1.3
1.0
2.1
0.6
1.6
0.5
0.9
0.8
Median^)
43.4
48.9
48.1
48.4
47.9
48.9
46.3
47.7
47.7
46.3
Min.e)
41.1
43.3
45.2
46.8
40.9
47.5
44.0
46.7
45.6
45.1
Max.*)
47.4
50.1
49.2
49.8
49.4
49.8
49.8
48.4
49.4
47.4
Second values
Mean
43.9
49.1
48.5
48.4
47.1
48.9
46.9
47.7
47.8
45.9
SDc)
1.3
1.1
0.9
1,0
2.2
0.6
1.7
0.6
1.1
0.9
Median*1)
43.7
49.1
49.0
48.5
47.5
48.8
47.1
47.7
47.8
46.0
Min.e)
42.0
47.4
46.7
46.3
41.1
47.4
42.8
46.5
46.0
44.4
Max.«)
46.9
51.1
49.8
49.8
49.4
49.9
50.9
48.8
49.8
47.4
SD
within
series
0.9
1.0
1.2
0.4
1.0
0.3
1.0
0.4
0.6
0.7
a) before the performance of any validity check
b) code of the respective laboratory
c) standard deviation (s) between series
d) median of all series
e) smallest value of all series
f) largest value of all series
The following calculations were performed:
The correlation coefficients i^n between known control and
unknown sample on the one hand and r^j between blind control
and unknown sample on the other hand, were calculated separ-
ately for each constituent and each laboratory.
First stage: First and second values (approximately 36 paired
values) were pooled. Then we took only the first values of the
double determinations (approximately 18 paired values). Each
rfcn and ç,é was tested (19) to see whether it was larger than zero
(one-sided test, error probability á = 5%). Then we compared
rfci with the corresponding ô^ç in both cases and for all labor-
atories and counted up how often rfci was larger than i^n and
conversely how often ÃÉ,É was smaller than i^n. Finally we tested(19) whether the first number was significantly larger than the
second one (one-sided test, á = 5%).
Second stage: Up to now all analytical data had been used.
The values of the unknown sample had not been checked by
means of the controls. From now on we used those series only
which met the following validity criterion;
Both values of the unknown sample were accepted as valid
in a series, provided both values of the known control of this
series were within the uncertainty limits of the assigned value
given by the manufacturer. Otherwise the whole series was
eliminated.
This check was performed on all series of all laboratories and
all constituents. Then we computed the standard deviation
Syy within and s^ between valid series, for each laboratory and
each constituent. As to s^, the standard deviations of the first
values and of the second values were evaluated separately and
then pooled to sb.
Third stage: In the following we used those series only which
met the following modified validity criterion:
The first value of the unknown sample was accepted as valid
in a series provided the first value of the known control as
well as the first value of the blind control of the series were
within the uncertainty limits of the respective assigned value
given by the manufacturer(s). In all other cases the whole series
was eliminated.
This check was performed on all series of all laboratories and all
constituents.
Results
Correlations between controls and unknown
sample
Table 3 contains all correlation coefficients rkn
between known control and unknown sample and rbl
between blind control and unknown sample. Those
Tab. 3. Correlation coefficients rjq, between known control and
unknown sample and rbi between blind control and
unknown sample.
Consti-
tuent
Creatinine
Glucose
Urea
Alanine
amino^
transferase
°
Using both values
Labor-
atory
rkn rbl
A
C
D
E
F
G
H
I
J
K
A
C
D
E
F
G
H
I
J
K
A
C
D
E
F
G
H
I
J
K
A
B
C
D
E
F
G
H
I
J
K
0.531*
0.328*
0.377*
0.023
0.107
0.258
0.776*
-.032
0.551*
0.289*
0.382*
-.122
0.571*
0.325*
0.237
0.069
0.572*
-.138
0.102
0.122
0.122
0.079
0.192
0.716*
0.332*
0.124
0.023
-.140
0.503*
0.208
0.103 ·
0.050
0.215
0.063
0.138
0.406*
0.177
0.312*
0.407*
0.359*
0.389*
0.665*
0.520*
0.836*
0.162
0.127
0.431*
0.812*
-.174
0.238
0.691*
0.122
0.170
0.725*
-.032
0.507*
0.588*
0.659*
0.014
0.553*
-.030
0.291*
0.093
0.727*
0,615*
0.343*
0.425*
0.167
-.166
0.483*
0.320*
0.321*
0.160
0.454*
0.589*
0.006
0.600*
0.522*
0.353*
0.169
0.147
0.432*
Using first values
only
?kn rbl
0.583*
0.442*
0.287
-.072
0.045
0.238
0.889*
-.050
0.555*
0,177
0.362
0.190
0.481*
0.443*
0.486*
0.152
0.558*
-.143
-.088
-.058
-.089
0.206
0.293
0.576*
-.060
0.463*
0.367
0.196
0.516*
0.297
-.184
0.240
0.375
0.057
-.004
0.448*
0.018
0.032
0.504*
0.513*
0.565*
0.638*
0.371
0.809*
0.252
0.115
0.359
0.829*
-.117
0.377
0.679*
0.473*
0.445*
0.723*
0.124
0.652*
0.584*
0.580*
0.048
0.597*
-.236
0.122
-,.222
0.753
0.587*
0.496*
0.346
0.367
-.150
0.648*
0.344
0.268
0.131
0.356
0.792*
-.178
0.581*
0.579*
0.299
0.322
0.220
0.735*
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Tab. 3. Continued.
Consti-
tuent ^
Using both values
Labor·
atorv
rkn
Aspartate
amino-
transferase
Creatine
kinase
7-Glutamyl-
transferase
A
B
C
E
F
G
H
I
J
K
L
A
C
D
E
F
G
H
J
K
A
C
D
E
F
G
H
I
J
K
Total number of *
A 11 1 _ ~~~ft
0.219
0.500*
0.499*
0.137
0.537*
-.047
0.392*
-.054
0.625*
0.096
0.544*
0.144
0.239
0.847*
-.247
0.169
-.117
0.124
0.176
0.160
-.087
0.439*
0.349*
0.406*
0.332*
0.326*
0.174
0.382*
0.140
0.303*
0.351*
33
- · u·
rbi
0.163
0.384*
0.301*
0.170
0.121
0.024
0.353*
0.057
0.511*
0.616*
0.561*
0.350*
0.019
0.146
0.211
0.616*
-.114
0.169
0.316*
0.571*
0.225
0.524*
0.369*
0.547*
0.323*
0.527*
0.604*
0.365*
-.023
-.089
0.194
42
Using first values
only
rkn
0.112
0.609*
0.507*
0.194
0.577*
-.086
0.434*
0.213
0.719*
0.049
0.566*
0.268
0.238
0.861*
-.217
0.012
-.057
-.008
-.013
0.300
0.097
0.299
0.256
0.424*
0.408*
0.133
0.121
0.349
0.063
0.256
0.065
24
_ *1___ 4.1.^ .
rbl
0.053
0.356
0.360
0.340
0.040
0.061
0.540*
0.029
0.613*
0.801*
0.575*
0.560*
0.238
0.199
0.149
0.685*
-.103
0.220
-.123
0.613*
0.071
0.420*
0.442*
0.561*
0.232
0.531*
0.615*
0.479*
0.062
-.114
0.259
32
Tab. 4. Number of laboratories and constituents witha) rbj > rkn.
Using both Using first
values values only
rbl > *kn 47 45
rbl < *kn 25 27
Total 72 72
a) for explanations see table 3.
a largely parallel course, whereas the magnitude of the
analytical results of the two sera might be quite different.
So it is reasonable to compute the two correlation coeffi-
cients rbj and rkn as measures of the parallel course of
each; this serves to check whether the blind control or
the known control better fulfills this criterion.
Since we wanted a measure for parallelity, we used the
correlation coefficients independently of the distribu-
tion of the analytical values.
Actually it happened that some correlation coefficients
were negative. But in this context negative correlation
coefficients do not make sense. So it seemed reasonable
to restrict ourselves to those laboratories and constitu-
ents with positive correlation coefficients rb! and rkn .
The corresponding results are given in table 5.
Comparison of these figures by means of the test (19)
again shows in both cases that rw > rkn occurs signi-
ficantly more frequently (error probability a = 5%).
Therefore it can be concluded that the blind control is
more parallel to the unknown sample, than is the known
control.
critical value (a = 5%) are starred (*).
rkn and rbl significantly (a = 5%) larger than zero are
starred.
If these significances occurred purely at random their
proportion relative to the number 72 of sets of analyt-
ical values could be expected to be about = 5%. In
fact, their proportion is significantly higher (19). Con-
sequently, controls and unknown sample are found to
be correlated3) so that it makes sense to compare rkn
and rbj. Table 4 contains the number of laboratories and
constituents with rw ^  rkn-
Comparison of these figures by means of a test (19)
shows in both cases that rbi > rkn occurs significantly .
more frequently than rbl < rkn (error probability
a = 5%).
The philosophy of internal quality control is based on
the assumption that control and unknown sample take
Tab. 5. Number of laboratories and constituents with3)
rbl ^  rkn D0th being positive.
rbl > rkn
?bl < rkn
Total
Both values
41
18
59
First values
only
36
19
55
3) We use the correlation coefficient here äs a familiar notion
in order not to anticipate the results of the following paper
(22). Moreover, the correlation between unknown sample
and the controls was expected.
a) for explanations see table 3.
Precision within and between series (using both
values and validity checks by means of the known
control only)
We started from 1272 series derived from all laboratories
and constituents. After the validity check based on the
known control 1225 series were left. There was only one
out of 72 sets of analytical values with sb > Sw, namely
one laboratory with creatine kinase, see figure 1.
Sw is a measure of precision within series. By experience,
Sw is indeed usually smaller than sb, the precision
between series. However, if sb exceeds s ,^ essentially the
analytical method is unstable from series to series so that
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Fig. 1. Analytical results for creatine kin se from the mentioned
laboratory.
Plotter printout
Ordinate: Creatine kinase (U/l].
Abscissa: Series no.
First values (solid line) and second values (dotted line) of
double determinations of all three sera are plotted against
the running number of series. In the controls the solid
horizontal lines give the assigned values and the dashed
ones their uncertainty limits. In the unknown sample how-
ever the dashed lines limit the range in which 95% of all
valid values of all other laboratories lie. The vertical dashed
lines facilitate the comparison of the sera. Furthermore, in
the unknown sample a · (a) indicates that this value is
eliminated by means of the known (blind) control. Mean
value x, standard deviation s, and coefficient of variation
CV of the first values of the double determinations are also
given for each serum.
the analytical values are systematically incorrect. There-
fore, this laboratory is eliminated from the later evalua-
tion of creatine kinase.
Efficiency of known and blind control (using
first values only and validity checks by means
of both controls)
We started from 1237 series left after the validity check
based on the known control only. By additional elimi-
nation based on both controls this figure was reduced
to 1197 valid series. The resulting elimination propor-
tion of 3.2% is caused by the blind control only. How-
CD.
^
Vft
é i i
• 1 - 4 - -4
\Λ é é
/ \f\\ ^ /\i/^^ W V i ~ vé é é
Ë
Ë
X = 15.1
S = 0 . 8 3
CV = 5.52
i '
B L I N D
.CONTROL
U N K N O W N
.SflMPLE
X = 12.2
S = I .15
CV = 9.41
Í ' Ã é ß ' Á ' Ë ' Á º ß 8 6 ^ 8i ' 4 ' Ý
Fig. 2. Analytical results for urea from the mentioned laboratory.
Plotter printout
Ordinate: Urea [mmol/lj.
Abscissa: Series no.
First values only of double determinations of all three
sera are plotted against the running number of series. For
the other details see figure 1.
ever, this cannot be explained as those 5% which might
statistically be expected to be eliminated when the
manufacturer's 95% uncertainty interval is used. This
statement is based on the fact that only about 57% of
these eliminated series were uniformly distributed over
all laboratories and constituents, whereas the remaining
43% were concentrated in two cases only:
Case 1: Urea, one laboratory (18 series, figure 2). The
standard deviation between series is extremely higji for
all three sera. But the uncertainty intervals of the two
control sera have different power: The uncertainty
interval of the blind control is relatively smaller in com-
parison with the known control. Furthermore, the co-
efficient of variation of the blind control is more than
double the value of the known control. So it is plausible
that values of 7 series of the blind control, but none of
the known control, are outside the limits. Therefore, all
series of urea of this laboratory are eliminated.
Case 2: ã-Glutamyltransferase, one laboratory (18 series,
figure 3). Similarly, the uncertainty interval of the blind
control is relatively smaller than that of the known con-
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Fig. 3. Analytical results for 7-glutamyltransferase from the
mentioned laboratory.
Plotter printout
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For detailsrsee figure 1.
trol and so leads to 10 eliminations. Therefore, all series
of r-glutamyltransferase of this laboratory are excluded.
In both cases the complete elimination is essential
because most values of the unknown sample differ sub-
stantially from the pool of values of all other labor-
atories. Incorporation of the eliminated values could
produce a systematically wrong assigned value.
In the above two cases the elimination is caused by the
blind control only, so that the additional efficiency of
this control is obvious. In two further cases the known
control primarily leads to the elimination:
Case 3: Glucose, one laboratory (15 series, figure 4).
Nine series are found invalid by means of the known
control and three of them by means of the blind control.
All series of glucose of this laboratory are eliminated.
Case 4: Creatine kinase, one laboratory (16 series,
figure 1). Six series are eliminated by means of both
controls $o that all series of creatine kinase of this
laboratory are excluded. This is essential because most
values of the unknown sample of this laboratory are
substantially lower than the pool of values of the
÷ = 5.
s = 0.23
CV = 4 .64
ô4 SERIES14
B L I N D
.CONTROL
10 12 14
UNKNOWN
„SflMPLE
X = 11 .6
S = 0 .24
CV r 2 -07
l i i i é I SERIES10 12 14
Fig. 4. Analytical results for glucose from the mentioned
laboratory.
Plotter printout
Ordinate: Glucose (mmol/lj.
Abscissa; Series no.
For details see figure 1.
others. The fact that only 6 series are found invalid is
explained by different properties of the sera so that
some deviations in the unknown sample are not dis-
covered by the controls.
Another reason for exclusion is due to creatinine, one
laboratory (17 series, figure 5). One series is eliminated
by means of the known control. But all values of the un-
known sample are much higher than the pool of values
of the other laboratories. Therefore, all series are ex-
cluded. The reason for this failure of controls is a
systematic error in performing the analyses of the un-
known sample, but not of the controls.
The number of laboratories remaining after these eli-
minations is given in table 1.
Discussion
The course of a blind control correlates better with the
unknown sample than does a known control. Further-
more, the effect of the blind control on the elimination
of laboratories is greater than the control effect related
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to the double determination. There was only one labor-
atory the deviating results of which were recognized by
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Fig. 5 Analytical results for cieatinine from the mentioned
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means of both controls. Two additional laboratories how-
ever had to be eliminated on the basis of the blind control
only.
The possibility of comparing precisions as described
above gives the main reason for the performance of
double determinations. Therefore, double determina-
tions seem to be unneccessary. We shall confirm this
conclusion in I.e. (20) using other arguments. Rather, it
is preferable to have a blind control. Both designs, either
double determinations of the unknown sample only or
single determination of the unknown sample as well
as the addition of the blind control, result in the same
analytical expenditure. For an optimal efficiency the
blind control should be very similar to the unknown
sample, with respect to e.g. same protein base, same
degree of turbidity, lyophilisate, and so on. Clearly,
the assigned values of the blind control and their un-
certainty limits must be established very carefully. An
analogous result is described in I.e. (21).
The laboratories remaining after the above eliminations
will be used for further evaluations in the following
papers (20,22,23).
Acknowledgements
This study was initiated by the Committee of Clinical Chemistry
oftheVDGH.
The authors thank G. von Seydlitz (Asid Bonz und Sohn GmbH),
A. Berke (Boehringer Ingelheim Diagnostika GmbH), W. Bablok,
A. Benozzi, F. Bosslet, M. Glocke (all Boehringer Mannheim
GmbH), W. von Thun (Goedecke AG), H.-G. Eisenwiener
(F. Hoffmann-La Roche & Co. AG), B. Carl (Dr. Bruno Lange
GmbH), F. Schindler (F. Merck), R. Spaethe (Merz und Dade,
Abteilung der American Hospital Supply Deutschland GmbH),
and D. Schlitzer (Technicon GmbH).
References
1. Passing, H., Glocke, M., Brettschneider, H. & M ller, B.
(1980) Lab. Med. 4, 154-159.
2. Hansert, E. & Stamm, D. (1980) J. Clin. Chem. Clin. Bio-
chem. 75,461-490.
3. Schumann, V. (1976) Med. Labor. 29, 271-276.
4. The National Committee for Clinical Laboratory Standards
(NCCLS), Calibration reference materials and control ma-
terials in clinical chemistry (1975).
5. Allen, J. R., Earp, R., Parrel jr., E. C. & Gruemer, H. D.
(1969) Clin. Chem. 15,1039-1044.
6. McCormick, W., Ingelfinger, J. A., Isakson, G. & Goldman, P.
(1978) New Engl. J. Med. 299, 1118-1121.
7. Barrels, H., Boehmer, M. & Heierli, C. (1972) Clin. Chim.
ActaJ7,193-197.
8. Helger, R. R., Rindfrey, H. & Hilgenfeldt, J. (1974),Z. Klin.
Chem. Klin. Biochem. 12, 344-349.
9. Ullmann, R. & Bonitz, K. (1976) Med. Labor, 29,137.
10. Barthelmai, W. & Czok, R. (1962) Klin. Wochenschr. 40,
585-589.
11. Schmidt, F. H. (1961) Klin. Wochenschr. 39, 1244-1247.
12. Slein, M. W., Cori, G. T. & Cori, C. F. (1950) J. Biol. Chem.
186, 763-780.
13. Fawcett, J. K. & Scott, J. E. (1960) J. Clin. Pathol. 13, 156.
14. Richterich, R. (1968) Klinische Chemie, Akad. Verlagsges.
Frankfurt am Main, 2nd edition, p. 254.
15. Deutsche Gesellschaft fur Klinische Chemie, Standardi-
sierung von Methoden zur Bestimmung von Enzymaktivit ten
in biologischen Fl ssigkeiten. Z. Klin. Chem. Klin. Biochem.
10,182 (1972).
16. Deutsche Gesellschaft f r Klinische Chemie, Standard-
Methode zur Bestimmung der Aktivit t der Creatin-Kinase.
J. Clin. Chem. Clin. Biochem. 75, 249 (1977).
17. Szasz, G., Waldenstroem, J. & Gruber, W. (1979) Clin. Chem.
25,446.
18. Szasz, G., Weimann, G., St hler, F., Wahlefeld, A.-W.,
Persijn, J. P. (1974) Z. Klin. Chem. Klin. Biochem. /2, 228.
19. Documenta Geigy, Wissenschaftliche Tabellen, Georg Thieme
Verlag, Stuttgart 1975.
20. Passing, H,, Bablok, W. & Glocke, M. (1981) J. Clin. Chem.
Clin. Biochem. 19,1167-1179.
21. Benozzi, A., Brettschneider, H., Glocke, M. & Bernt, E.
(1981) Med. Labor, in press.
22. Passing, H. (1981) J. Clin. Chem. Clin. Biochem. 19,
1145-1151.
23. Passing, H. (1981) J. Clin. Chem. Clin. Biochem. 19,
1153-1166.
For repr.int requests:
Gesch ftsstelle des
Verband der Diagnostica- und
Diagnostieagef te-Hersteller (VDGH)
Karlstr. 21
D-6000 Frankfurt l
J. Clin. Chem. Clin. Bioehem. / VoL 19, 1981 /No. 11
